Drug development has long relied on animal testing to evaluate the safety and effectiveness of new therapies before they reach human clinical trials. While animal models have played an important role in biomedical research, they often fail to accurately predict how treatments will perform in humans. The result is high drug failure rates, lengthy development timelines, and rising research costs.
Frontier Bio is working to change that.
Founded with the mission of improving both preclinical research and regenerative medicine, Frontier Bio is developing living, three-dimensional human tissue models and patient-derived vascular grafts that more closely replicate human biology. By engineering living tissues from a patient’s own stem cells, the company aims to provide researchers with more predictive models for drug testing while also addressing the critical shortage of transplantable tissues and organs.
Frontier Bio was featured on the Propel(x) platform in 2024, giving accredited investors the opportunity to explore an innovative company developing next-generation human tissue technologies.
Building Human-Based Platforms for Research and Regenerative Medicine
Unlike traditional preclinical testing methods that rely heavily on animal models, Frontier Bio is developing human-based tissue platforms that serve multiple applications across the life sciences ecosystem.
Its technologies are designed to support:
- More predictive preclinical drug testing
- Human tissue models for biomedical research
- Patient-derived vascular grafts for regenerative medicine
- Advanced tissue engineering applications
- Future organ replacement technologies
By combining tissue engineering with stem cell science, Frontier Bio is positioning itself at the intersection of biotechnology, regenerative medicine, and precision healthcare.
Industry Momentum Is Shifting Toward Human-Relevant Research
The broader research ecosystem is increasingly embracing alternatives to animal testing.
In 2026, the U.S. National Institutes of Health (NIH) launched the Office of Research Innovation, Validation, and Application (ORIVA), an initiative focused on accelerating the development and adoption of human-based research models. The program reflects growing regulatory and scientific interest in technologies that better predict human outcomes while reducing reliance on animal testing.
As regulators, pharmaceutical companies, and academic researchers seek more predictive research tools, companies developing human tissue platforms may play an increasingly important role in the future of drug development.
Recent Milestones Reflect Scientific and Commercial Progress
Frontier Bio has continued to advance both its research platform and commercial activities through several notable achievements.
KingsCrowd ICW 2026 Champion
The company was recognized as a KingsCrowd ICW 2026 Champion, highlighting its innovation, execution, and commercial potential within the early-stage startup ecosystem.
Best Paper Award at the 50th Annual VESS Meeting
Frontier Bio also received the Best Paper Award at the 50th Annual VESS Meeting for its research on a single-surgery regenerative vascular graft, recognizing the scientific significance of its regenerative medicine platform.
Early Commercial Traction
In addition to its research achievements, Frontier Bio has demonstrated meaningful commercial progress.
The company has reported more than $5.5 million in cumulative preclinical sales and has successfully completed over 25 commercial projects, demonstrating growing demand for its human tissue technologies while continuing to expand its scientific platform.
This combination of commercial validation and research progress differentiates Frontier Bio from many early-stage biotechnology companies that remain focused solely on laboratory development.
Experienced Leadership Driving Innovation
Frontier Bio is led by an experienced team with expertise spanning tissue engineering, regenerative medicine, translational research, and biotechnology. CEO Eric Bennett brings a strong background in developing advanced technologies, while the company’s scientific leadership includes specialists in 3D cell culture, vascular engineering, and in vitro tissue development.
Supported by notable investors including Jonathan Yaffe, CEO of AnyRoad, and Nishant Bhat, General Partner at Carbon Silicon Ventures, Frontier Bio combines scientific expertise with experienced strategic backing as it advances its platform.
Frontier Bio is also actively raising capital to accelerate the commercialization of its human tissue models, expand its regenerative medicine platform, and advance the development of patient-derived living vascular grafts.
Bridging Biotechnology and Regenerative Medicine
Frontier Bio’s vision extends beyond improving preclinical research.
By engineering living tissues using patient-derived stem cells, the company aims to create solutions that not only improve drug development but also address critical healthcare challenges, including the shortage of transplantable tissues and organs.
This dual focus on research tools and therapeutic applications positions the company within two rapidly evolving sectors of healthcare innovation.
Looking Ahead
The future of drug development increasingly depends on technologies that better reflect human biology.
As pharmaceutical companies seek more predictive preclinical models and healthcare systems look toward regenerative medicine to address unmet clinical needs, human tissue engineering is becoming an increasingly important area of innovation.
Frontier Bio is contributing to this transformation by developing living human tissue platforms that combine scientific rigor with early commercial validation. Through advances in tissue engineering, stem cell science, and regenerative medicine, the company is helping shape the next generation of biomedical research.
We congratulate the Frontier Bio team on their recent achievements and look forward to following their continued progress.
